Hong Kong
· Delayed Price · Currency is HKD Pharmaron Beijing Statistics
Total Valuation
Pharmaron Beijing has a market cap or net worth of HKD 46.38 billion. The enterprise value is 50.55 billion.
| Market Cap | 46.38B |
| Enterprise Value | 50.55B |
Important Dates
The next estimated earnings date is Thursday, March 27, 2025.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | Jun 27, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | -0.35% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.13B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.59, with an EV/FCF ratio of 123.09.
| EV / Earnings | 24.23 |
| EV / Sales | 3.99 |
| EV / EBITDA | 18.59 |
| EV / EBIT | 31.64 |
| EV / FCF | 123.09 |
Financial Position
The company has a current ratio of 1.71, with a Debt / Equity ratio of 0.42.
| Current Ratio | 1.71 |
| Quick Ratio | 1.32 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 2.31 |
| Debt / FCF | 15.75 |
| Interest Coverage | 6.16 |
Financial Efficiency
Return on equity (ROE) is 13.58% and return on invested capital (ROIC) is 4.79%.
| Return on Equity (ROE) | 13.58% |
| Return on Assets (ROA) | 4.04% |
| Return on Capital (ROIC) | 4.79% |
| Revenue Per Employee | 643,729 |
| Profits Per Employee | 102,814 |
| Employee Count | 20,295 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 7.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.71% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -36.71% |
| 50-Day Moving Average | 14.37 |
| 200-Day Moving Average | 10.74 |
| Relative Strength Index (RSI) | 40.20 |
| Average Volume (20 Days) | 9,925,758 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmaron Beijing had revenue of HKD 13.06 billion and earned 2.09 billion in profits. Earnings per share was 1.18.
| Revenue | 13.06B |
| Gross Profit | 4.46B |
| Operating Income | 1.65B |
| Pretax Income | 2.37B |
| Net Income | 2.09B |
| EBITDA | 2.60B |
| EBIT | 1.65B |
| Earnings Per Share (EPS) | 1.18 |
Balance Sheet
The company has 2.88 billion in cash and 6.47 billion in debt, giving a net cash position of -3.59 billion.
| Cash & Cash Equivalents | 2.88B |
| Total Debt | 6.47B |
| Net Cash | -3.59B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 15.54B |
| Book Value Per Share | 8.38 |
| Working Capital | 3.26B |
Cash Flow
In the last 12 months, operating cash flow was 2.76 billion and capital expenditures -2.35 billion, giving a free cash flow of 410.68 million.
| Operating Cash Flow | 2.76B |
| Capital Expenditures | -2.35B |
| Free Cash Flow | 410.68M |
| FCF Per Share | n/a |
Margins
Gross margin is 34.12%, with operating and profit margins of 12.61% and 15.97%.
| Gross Margin | 34.12% |
| Operating Margin | 12.61% |
| Pretax Margin | 18.13% |
| Profit Margin | 15.97% |
| EBITDA Margin | 19.88% |
| EBIT Margin | 12.61% |
| FCF Margin | 3.14% |
Dividends & Yields
Pharmaron Beijing does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | -33.08% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 29.13% |
| Buyback Yield | -0.06% |
| Shareholder Yield | -0.06% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on July 18, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Jul 18, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
Pharmaron Beijing has an Altman Z-Score of 3.7.
| Altman Z-Score | 3.7 |
| Piotroski F-Score | n/a |